Jefferies Maintains Bullish Stance on Amarin (AMRN) Despite Self Commercialization News
Tweet Send to a Friend
Jefferies reiterated their Buy and $28 price target on Amarin Corporation (NASDAQ: AMRN) following the company's move to self-commercialize Vascepa.
This article: 130 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 130 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
